COVID-19 Treatment Guidelines

Overview

This review, published in Infectious Disease Reports (Jirjees et al., 2021), is not a treatment guideline itself. It compares how national COVID-19 treatment guidelines differed in their approach to managing patients during the first year of the pandemic, and asks whether they reflected best available evidence.

What was reviewed

The authors included published guidelines from 23 countries and three reference guidelines, up to the end of 2020. They summarise the treatment groups these documents covered, including antiviral, antimalarial and antibacterial agents, corticosteroids, immunotherapy, anticoagulation and other pharmacological approaches, and they map where countries agreed and where they diverged.

Why guidelines differed

The review links variation between countries to practical factors: the cost of medicines, access to and availability of specific treatments, and the capacity of healthcare facilities. Bringing these documents together in one place makes it easier to see how local circumstances shaped recommendations.

Main conclusion

Although many treatment groups appeared in guidelines worldwide, the authors conclude that there was no evidence that most of these medicines reduced COVID-19 mortality over the period studied. The review is a useful record of how guidance evolved under uncertainty.

Important note

This review reflects the evidence available at the end of 2020. Treatment recommendations for COVID-19 have changed substantially since then, and clinicians should consult current national and international guidance for patient care.

How to read it

The review is best used to understand why recommendations differed between countries and how quickly they changed as trial results emerged, rather than as a source of treatment advice. It also illustrates the difficulty of issuing clinical guidance while the evidence is still accumulating.

Who it is for

Infectious disease specialists, clinical pharmacists, public health professionals and anyone studying how clinical guidance develops during an emerging epidemic.